Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease.
A 38 year old patient with megalencephaly, mental retardation, and lifelong tremor developed levodopa responsive parkinsonism in his mid-30s followed by the appearance of dyskinesiae, motor fluctuations, hallucinations, and dementia. Brain MRI showed, as well as other changes, iron deposition in the globus pallidus, substantia nigra, and the pulvinar of the thalamus. Postmortem examination disclosed depigmentation of the substantia nigra pars compacta with neuronal loss, gliosis, and Lewy body formation. Axonal dystrophic spheroids, neuronal loss, calcification, and iron deposition were found in the substantia nigra pars reticulata. Less severe changes without neuronal loss were seen in the globus pallidus. This combination of megalencephaly with neuroaxonal changes predominantly in the pars reticulata and Lewy body degeneration isolated to the substantia nigra pars compacta has not been previously reported.
Tuite
P J
PJ
Morton and Gloria Shulman Movement Disorder Centre, Toronto, Ontario, Canada.
Provias
J P
JP
Lang
A E
AE
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001921:Brain / Q000473:pathology*; D006801:Humans; D006984:Hypertrophy; D007980:Levodopa / Q000627:therapeutic use*; D016631:Lewy Bodies / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D006211:Pantothenate Kinase-Associated Neurodegeneration / Q000150:complications / Q000473:pathology*; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D013378:Substantia Nigra / Q000473:pathology
D000978:Antiparkinson Agents; D007980:Levodopa